Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline.
作者信息
Chedid Victor, Vijayvargiya Priya, Camilleri Michael
机构信息
Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota.
出版信息
Clin Gastroenterol Hepatol. 2018 Mar;16(3):336-338. doi: 10.1016/j.cgh.2017.11.025. Epub 2017 Nov 16.
Abstract
摘要
相似文献
1
Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline.联邦不良事件报告系统在评估埃卢多啉不良事件报告方面的优势与局限
Clin Gastroenterol Hepatol. 2018 Mar;16(3):336-338. doi: 10.1016/j.cgh.2017.11.025. Epub 2017 Nov 16.
2
Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.治疗肠易激综合征时使用 Eluxadoline 增加胰腺炎风险。
Clin Gastroenterol Hepatol. 2018 Mar;16(3):378-384.e2. doi: 10.1016/j.cgh.2017.08.006. Epub 2017 Aug 10.
3
Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.关于 Eluxadoline 治疗腹泻型肠易激综合征的最新进展：患者选择和观点。
Drug Des Devel Ther. 2020 Apr 9;14:1391-1400. doi: 10.2147/DDDT.S216056. eCollection 2020.
4
Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.鲁比前列酮治疗腹泻型肠易激综合征患者的安全性
Am J Gastroenterol. 2017 Feb;112(2):365-374. doi: 10.1038/ajg.2016.542. Epub 2016 Dec 6.
5
Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report.胆囊切除术后患者中与埃洛昔康相关的胰腺炎：一例报告
Del Med J. 2017 Mar;89(3):90-92.
6
Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.依鲁替尼在腹泻型肠易激综合征中的研究进展
Drugs. 2017 Jun;77(9):1009-1016. doi: 10.1007/s40265-017-0756-7.
7
In brief: Pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder.简而言之：在无胆囊患者中使用埃卢多啉（Viberzi）引发的胰腺炎。
Med Lett Drugs Ther. 2017 Apr 24;59(1519):70.
8
Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.Eluxadoline 治疗对洛哌丁胺治疗不佳的腹泻型肠易激综合征患者的疗效和安全性：RELIEF 研究 4 期。
Am J Gastroenterol. 2019 Sep;114(9):1502-1511. doi: 10.14309/ajg.0000000000000327.
9
Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.在伴有腹泻的肠易激综合征患者的 2 期和 3 期研究中，埃卢昔多oline 表现出缺乏滥用潜力。
Clin Gastroenterol Hepatol. 2017 Jul;15(7):1021-1029.e6. doi: 10.1016/j.cgh.2017.01.026. Epub 2017 Feb 3.
10
Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.用于治疗腹泻型肠易激综合征的埃卢多啉
Expert Opin Pharmacother. 2016 Jul;17(10):1395-402. doi: 10.1080/14656566.2016.1182982. Epub 2016 Jun 8.
引用本文的文献
1
Editorial: Emerging trends in real-world pharmacoepidemiology: 2023.社论：2023年真实世界药物流行病学的新趋势
Front Pharmacol. 2025 Apr 15;16:1601477. doi: 10.3389/fphar.2025.1601477. eCollection 2025.
2
A review of the safety of sodium-glucose co-transporter-2 inhibitors.钠-葡萄糖协同转运蛋白2抑制剂的安全性综述
Diabetes Obes Metab. 2025 Jul;27(7):3598-3606. doi: 10.1111/dom.16385. Epub 2025 Apr 8.
3
Investigating the Benefit-Risk Profile of Drugs: From Spontaneous Reporting Systems to Real-World Data for Pharmacovigilance.研究药物的获益-风险概况：从自发报告系统到用于药物警戒的真实世界数据。
Methods Mol Biol. 2025;2834:333-349. doi: 10.1007/978-1-0716-4003-6_16.
4
Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.与利奈唑胺给药相关的药物不良事件：一项使用FAERS数据库的2004年至2023年真实世界药物警戒研究。
Front Pharmacol. 2024 Feb 16;15:1338902. doi: 10.3389/fphar.2024.1338902. eCollection 2024.
5
A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database.对 FAERS 数据库中提交的阿片类药物相关不良事件进行系统分析和数据挖掘。
Exp Biol Med (Maywood). 2023 Nov;248(21):1944-1951. doi: 10.1177/15353702231211860. Epub 2023 Dec 30.
6
Metabolic modeling of sex-specific liver tissue suggests mechanism of differences in toxicological responses.性别特异性肝组织的代谢建模提示毒理学反应差异的机制。
PLoS Comput Biol. 2023 Aug 21;19(8):e1010927. doi: 10.1371/journal.pcbi.1010927. eCollection 2023 Aug.
7
A retrospective study of adverse drug events in anticoagulant administration with relevance to COVID-19.一项关于抗凝药物给药中与COVID-19相关的药物不良事件的回顾性研究。
Heliyon. 2023 Mar;9(3):e13763. doi: 10.1016/j.heliyon.2023.e13763. Epub 2023 Feb 24.
8
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.功能性肠病伴腹泻：欧洲胃肠病学联合会和欧洲神经胃肠病学和动力学会临床指南。
United European Gastroenterol J. 2022 Jul;10(6):556-584. doi: 10.1002/ueg2.12259. Epub 2022 Jun 13.
9
Hypertensive events after the initiation of contemporary cancer therapies for breast cancer control.当代乳腺癌控制治疗方案启动后高血压事件的发生情况。
Cancer Med. 2023 Jan;12(1):297-305. doi: 10.1002/cam4.4862. Epub 2022 May 27.
10
Comparison of Online Patient Reviews and National Pharmacovigilance Data for Tramadol-Related Adverse Events: Comparative Observational Study.在线患者评论与全国药物警戒数据中曲马多相关不良事件的比较：观察性比较研究。
JMIR Public Health Surveill. 2022 Jan 4;8(1):e33311. doi: 10.2196/33311.
本文引用的文献
1
Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.治疗肠易激综合征时使用 Eluxadoline 增加胰腺炎风险。
Clin Gastroenterol Hepatol. 2018 Mar;16(3):378-384.e2. doi: 10.1016/j.cgh.2017.08.006. Epub 2017 Aug 10.
2
Irritable Bowel Syndrome.肠易激综合征
N Engl J Med. 2017 Jun 29;376(26):2566-2578. doi: 10.1056/NEJMra1607547.
3
Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice.《罗马IV型结直肠疾病标准的更新：对临床实践的影响》
Curr Gastroenterol Rep. 2017 Apr;19(4):15. doi: 10.1007/s11894-017-0554-0.
4
Sphincter of Oddi Function and Risk Factors for Dysfunction.Oddi括约肌功能及功能障碍的危险因素。
Front Nutr. 2017 Jan 30;4:1. doi: 10.3389/fnut.2017.00001. eCollection 2017.
5
Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches.肠易激综合征：病理生理学与当前治疗方法
Handb Exp Pharmacol. 2017;239:75-113. doi: 10.1007/164_2016_102.
6
Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.鲁比前列酮治疗腹泻型肠易激综合征患者的安全性
Am J Gastroenterol. 2017 Feb;112(2):365-374. doi: 10.1038/ajg.2016.542. Epub 2016 Dec 6.
7
Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.埃卢多啉治疗腹泻型肠易激综合征的临床潜力。
Ther Clin Risk Manag. 2016 May 13;12:771-5. doi: 10.2147/TCRM.S83722. eCollection 2016.
8
Eluxadoline for Irritable Bowel Syndrome with Diarrhea.Eluxadoline 治疗腹泻型肠易激综合征。
N Engl J Med. 2016 Jan 21;374(3):242-53. doi: 10.1056/NEJMoa1505180.
9
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.在一项 2 期研究中，Eluxadoline 使腹泻型肠易激综合征患者受益。
Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.
10
Peripheral mechanisms in irritable bowel syndrome.肠易激综合征的外周机制
N Engl J Med. 2012 Oct 25;367(17):1626-35. doi: 10.1056/NEJMra1207068.
Zotero 插件